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Abstract
Purpose Clevudine 30 mg showed potent antiviral
activity with a marked post-treatment antiviral effect.
However, long-term treatment with clevudine monotherapy
induced resistance and myopathy in some cases. The
objective of this study is to evaluate the preliminary effi-
cacy and safety of the combination of clevudine 20 mg and
adefovir compared to clevudine monotherapy.
Methods Seventy-four patients were randomized to either
a combination of clevudine 20 mg and adefovir or clevu-
dine 20 or 30 mg and were treated for 2 years. The viral
kinetics for 24 weeks, virological response [VR; hepatitis
B virus (HBV) DNA less than 300 copies/ml], and the
biochemical response [BR; normal alanine aminotransfer-
ase (ALT)] were assessed.
Results There was no difference in baseline characteris-
tics among the three groups. Viral kinetics study showed no
statistically significant difference among them during
24 weeks. The combination group showed 95 % virologi-
cal response with a statistically significant difference
compared to the clevudine 30 mg (67 %) and 20 mg
(71 %) groups (p = 0.0376). Biochemical response rates
were similar in all groups (78–94 %). No resistance was
reported in the combination group, while 20 % of patients
treated with clevudine 30 mg or 20 mg reported resistance
during 2 years. Muscle-related symptoms such as myalgia
(1 in clevudine 30 mg, 1 in the combination group) and
muscle weakness (1 in clevudine 30 mg, 2 in clevudine
20 mg) were reported in five patients (7 %); of these, three
patients discontinued the study.
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Conclusion We concluded that the combination of
clevudine 20 mg and adefovir produced a potent antiviral
response together with a good resistance profile compared
to clevudine monotherapy at 96 weeks in this pilot study.
Keywords Adefovir  Clevudine  Combination therapy 
Hepatitis B virus  Resistance  Viral kinetics
Introduction
Although effective vaccines are available in many coun-
tries, hepatitis B virus (HBV) infection still constitutes a
global health threat since it can develop into liver cirrhosis
and hepatocellular carcinoma [1–3].
There are several oral antiviral agents, including lami-
vudine, adefovir, telbivudine, entecavir, and tenofovir,
available worldwide, and clevudine in Korea the and
Philippines, for the treatment of HBV infection. These
drugs were used as monotherapy in their clinical trials.
However, drug-induced mutations often emerged during
monotherapy with nucleos(t)ides, which were associated
with viral breakthrough and clinical deterioration [4].
Recently, the combination of nucleos(t)ides has been rec-
ommended to avoid such mutations [5] despite its non-
synergic effect [6].
Clevudine [7] showed very potent antiviral activity with
the unique advantage of sustained viral suppression after
withdrawal of treatment, which was demonstrated in sev-
eral clinical studies [8–10]. However, long-term therapy
showed the development of drug resistance [(0.7, 7.6 %)
for 1 year] [11, 12] and skeletal myopathy [(1.7, 3.9 %) for
96 weeks] [12–15]. The clevudine-related mutation was
rtM204I, as reported in previous publications [16]. Ade-
fovir dipivoxil, which is an acyclic phosphonate, is not a
highly potent drug against wild-type hepatitis B virus, but
relatively potent against mutations with rtM204I [17–19].
In this study, we predicted that combination treatment
with clevudine and adefovir may have additive or syner-
gistic antiviral activity in patients with chronic hepatitis B
because adefovir acts as a chain terminator and reduces the
emergence of resistance.
Global studies on clevudine were voluntarily suspended
in the USA by the sponsor because of the myopathy
reported in Korea; clevudine had only been approved in
Korea at that time. However, the Korean FDA scrutinized
all of the safety data including muscle-related symptoms
and then decided that clevudine could be marketed because
its associated myopathy is not life threatening and is
reversible when the patient is taken off the drug. Based on
the results of Emax modeling using AAUCMB (HBV DNA
average area under the curve minus baseline), the maximal
predicted treatment efficacy of clevudine was 77, 91, and
94 % with doses of 10, 30, and 50 mg, QD, respectively
[8].
We speculate that the reduced amount of clevudine at
20 mg can produce almost the same antiviral activity as
clevudine 30 mg based on Emax modeling and may reduce
the incidence of myopathy.
This study was designed to evaluate the preliminary
antiviral activity and safety of the combination of clevu-
dine 20 mg and adefovir versus monotherapy of clevudine
30 mg and 20 mg.
Materials and methods
Study design
This was a prospective, randomized, open-label trial to
evaluate the preliminary efficacy and safety of the com-
bination of clevudine 20 mg and adefovir compared to
clevudine monotherapy in chronic hepatitis B patients
enrolled at eight clinical centers in South Korea. All
patients were randomly assigned to be treated with either
clevudine 30 mg, 20 mg, or a combination of clevudine
20 mg and adefovir in a 1:1:1 ratio. The randomization list
was produced using SAS before the study. Randomization
was done with stratification on the basis of the study site, in
blocks of three or six.
Patients were monitored at baseline, days 4, 7, 10, 14,
weeks 3, 4, 8, 12, 24, 36, 48, 60, 72, 84, and 96 during the
study period. Patients underwent physical examinations
and blood samplings to measure laboratory parameters and
HBV DNA levels according to the protocol. A viral
kinetics study during the 24-week treatment period was
also performed for all the enrolled patients.
The study was conducted in compliance with the prin-
ciples of the Declaration of Helsinki and in accordance
with Good Clinical Practice guidelines. Written informed
consent, which was approved by the Institutional Review
Board, was obtained from all of the subjects before they
were examined for eligibility criteria. This study is regis-
tered as NIH clinical trial NCT01264354.
Study population
Eligible patients were 18 years and older and had been
hepatitis B surface antigen positive for at least 6 months.
Patients had HBV DNA levels higher than 1 9 105 copies/ml
and abnormal ALT levels. Patients were asked to give
written informed consent prior to study start and to comply
with the study requirements. Patents who had been
receiving interferon or peg-interferon within 6 months
before enrollment were excluded. Patients previously
treated with clevudine, lamivudine, adefovir, entecavir,
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telbivudine, tenofovir, or any other investigational drug for
HBV infection were also excluded. The exclusion criteria
included currently receiving antiviral, immunomodulatory,
cytotoxic, or corticosteroid therapy; clinical evidence of
decompensated liver disease such as total bilirubin
C2.0 mg/dl; prothrombin time C1.7 (INR); albumin
\3.5 g/dl; co-infection with hepatitis C, D, or the human
immunodeficiency virus; evidence of ascites, variceal
hemorrhage, or hepatic encephalopathy or hepatocellular
carcinoma; history of liver transplantation. Patients who
were pregnant or breast-feeding were also excluded.
Efficacy endpoints
The primary endpoint was the proportion of patients with
HBV DNA less than 300 copies/ml by real-time PCR at
week 24. HBV DNA levels were measured at a central
laboratory using the COBAS AmpliPrep/COBAS TaqMan
HBV Test, v2.0 (Roche, Branchburg, NJ, USA), with a
detection limit of 116 copies/ml.
Secondary endpoints included the reduction in HBV
DNA, as defined as a mean log10 decrease from baseline, the
proportion of patients with normal ALT, hepatitis B envelop
antigen (HBeAg) loss, and/or seroconversion. The viral
breakthrough was defined as a 1 log10 increase from nadir
during the treatment period. RFMP analysis (Invitrogen,
Carlsbad, CA, USA) on rtM204 and rtM180 sites was per-
formed on the patients who showed viral breakthrough.
Viral kinetics over the first 24 weeks
Serial HBV DNA samples were analyzed by a viral load
function previously applied to the clearance kinetics of
HBV from serum during a lamivudine and clevudine viral
dynamics study [20]. The efficacy (e) of inhibition of viral
production, free virus clearance rate constant (l), and
infected cell loss rate constant (a) were determined by
fitting the viral load function to the data using non-linear
regression.
VðtÞ ¼ V0el t þ ð1  eÞlV0ðe
a t  el tÞ
l  a
Safety analysis
Safety analysis included data from all 73 eligible patients
who received at least one dose of study medication after
randomization. Adverse events (AE), serious adverse events
(SAE), and laboratory toxicity were included in the safety
evaluations. If toxicities were not presented at baseline but
appeared during the trial, or worsened in severity from
baseline, laboratory toxicities were recorded. Muscle-related
symptoms, including myopathy, were evaluated according
to the guideline attached to the protocol.
Statistical analysis
The results were analyzed on an intention-to-treat basis for
the efficacy analysis. Patients discontinuing the study after
receiving the first study drug dose were included in the
efficacy analysis until their discontinuation. The patients
who received at least one of the study medications after
randomization were included in the safety analysis.
Statistical analysis was performed using SAS version
9.2 (SAS Institute, Cary, NC, USA). Determination of
statistical significance was performed with an alpha level
of 0.05. Comparisons of categorical variables were per-
formed by chi-square test or Fisher’s exact test, and con-




A total of 73 eligible patients were enrolled at 8 sites and
randomly assigned to receive the clevudine 30 mg daily
(n = 25), clevudine 20 mg daily (n = 24), or the combi-
nation (clevudine 20 mg and adefovir) daily (n = 24).
Baseline characteristics including the HBV DNA level and
ALT levels were similar among the three groups (Table 1).
At baseline, HBeAg-positive patients were 72 % (N = 18),
63 % (N = 15), and 63 % (N = 15) in the clevudine
30 mg, 20 mg, and combination group, respectively.
A total of 16 patients withdrew from the study. Hence,
57 patients (18 in the clevudine 30 mg group, 17 in the
clevudine 20 mg group, and 22 in the combination group)
completed the 96-week treatment period. Seven patients
discontinued the study in the clevudine 30 mg group
because of resistance (4), adverse events (2), and loss to
follow-up (1); 7 patients in the clevudine 20 mg group
because of resistance (3), withdrawal of consent (2),
adverse events (1), and loss to follow-up (1); 2 patients in
the combination group because of withdrawal of consent
(2). For the viral kinetics analysis, 24, 23, and 20 patients
were included in the clevudine 30 mg, 20 mg, and com-
bination groups, respectively.
Virologic and serologic endpoints
The proportions of patients with HBV DNA levels less than
300 copies/ml by real-time PCR assay at 24 weeks, which
was a primary efficacy endpoint, were 60, 59, and 57 % in
the clevudine 30 mg, 20 mg, and combination groups,
respectively, without a statistically significant difference
(p = 0.9688) (Table 2). The proportions of patients with
HBV DNA levels less than 300 copies/ml at week 96 were
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67, 71, and 95 % in the clevudine 30 mg, 20 mg, and
combination groups, respectively, which showed statisti-
cally significant differences (p = 0.0376).
The mean HBV DNA changes from baseline at week 96
were -4.32 ± 1.63, -4.86 ± 1.24, and -5.26 ± 1.42
log10 copies/ml in the clevudine 30 mg, 20 mg, and com-
bination groups, respectively, which did not show statisti-
cally significant differences (p \ 0.3534) (Fig. 1). At week
96, the rates of HBeAg loss (21 % in the clevudine 30 mg,
40 % in the clevudine 20 mg, and 21 % in the combination
group) and/or HBeAg seroconversion (7 % in the clevu-
dine 30 mg, 40 % in the clevudine 20 mg, and 21 % in the
combination group) were comparable among the three
groups (p = 0.5809, 0.1684). Viral breakthroughs were
observed in 28 % of the clevudine 30 mg, 17 % of the
clevudine 20 mg, and 0 % of the combination group,
which was significantly different (p = 0.0149). Among
them, six patients in the clevudine 30 mg and five patients
in the clevudine 20 mg group showed genotypic mutation
at rt204I; three of these patients showed double mutations
at rtM204I and rtL180M. In conclusion, clevudine-related
mutation was reported in 20 % of the clevudine mono-
therapy group, while no viral breakthrough was observed in
the combination group.
Viral kinetics over the first 24 weeks
Viral dynamics over the first 24 weeks were analyzed for
67 subjects who completed treatment at 24 weeks. Table 3
summarizes the estimated parameters by treatment group.
The p values of the Kruskal–Wallis test were 0.934, 0.489,
and 0.173 for e, l, and a, respectively, which did not show
statistically significant differences in the median estimates
among the three groups.
Biochemical endpoints
The proportions of patients who had normal ALT at week
96 were 78, 94, and 86 % in the clevudine 30 mg, 20 mg,
Table 1 Baseline characteristics
Characteristics CLV 30 mg (n = 25) CLV 20 mg (n = 24) CLV 20 mg ? ADV 10 mg (n = 24) p value
Male (%) 52.00 62.50 50.00 0.6451a
Age (year) 44.16 ± 10.14 45.08 ± 12.83 48.92 ± 11.73 0.3233b
Weight (kg) 64.66 ± 12.00 64.07 ± 11.05 64.65 ± 12.71 0.9806b
HBV DNA (log copies/ml)d 7.21 ± 1.41 7.47 ± 1.04 7.31 ± 1.45 0.5257c
ALT (U/l) 73.96 ± 62.02 132.63 ± 145.13 125.79 ± 162.46 0.2437c
HBsAg (log IU/ml)e 3.53 ± 0.78 3.66 ± 0.68 3.64 ± 0.68 0.8302b
HBeAg positive (%) 72.00 62.50 62.50 0.7193a
LC (%) 32.00 25.00 20.83 0.6661a




d 013-R007 (CLV 20 mg) was excluded because of missing data
e 57 patients (CLV 30 mg: 18, CLV 20 mg: 17, CLV 20 mg ? ADV 10 mg: 22) who completed the week 96 visit




b Fisher’s exact test
CLV 30 mg CLV 20 mg CLV 20 mg ? ADV 10 mg p value
Virologic response (\300 copies/ml)
Week 24 60.00 % (15/25) 59.09 % (13/22) 56.52 % (13/23) 0.9688a
Week 48 66.67 % (16/24) 70.00 % (14/20) 73.91 % (17/23) 0.8629a
Week 72 63.64 % (14/22) 66.67 % (12/18) 81.82 % (18/22) 0.3692a
Week 96 66.67 % (12/18) 70.59 % (12/17) 95.45 % (21/22) 0.0376b
Biochemical response (normal ALT)
Week 24 76.00 % (19/25) 81.82 % (18/22) 69.57 % (16/23) 0.6313a
Week 48 91.67 % (22/24) 85.00 % (17/20) 82.61 % (19/23) 0.6695b
Week 72 81.82 % (18/22) 88.89 % (16/18) 81.82 % (18/22) 0.8290b
Week 96 77.78 % (14/18) 94.12 % (16/17) 86.36 % (19/22) 0.4053b
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and combination groups, respectively (p \ 0.4053)
(Table 2).
Safety and tolerability
During the 96-week treatment period, the incidences of
adverse events were similar among the three groups: 68,
63, and 58 % in the clevudine 30 mg, 20 mg, and combi-
nation groups, respectively (p \ 0.7808). The most fre-
quent adverse events, occurring in more than 10 % of
patients, were hypertension (20 %) and CPK elevation
(12 %) in the clevudine 30 mg group and upper respiratory
tract infection (17 %) and CPK elevation (13 %) in the
clevudine 20 mg group. No event occurred in more than
10 % of patients in the combination group. The incidence
of serious adverse events during treatment was 12 %
(3 patients) only in the clevudine 30 mg group. The SAEs
of angina pectoris, arrhythmia, and inguinal hernia reported
by three patients were mild or moderate in severity and
considered to be unrelated to the study drugs.
Muscle-related symptoms such as myalgia and muscle
weakness were reported in two patients (1 of myalgia, 1 of
muscle weakness) in the clevudine 30 mg group, two
patients (muscle weakness) in the clevudine 20 mg group,
and one patient (myalgia) in the combination group.
Laboratory toxicities at grade 3 or higher were reported
in eight patients, three patients, and four patients in the
clevudine 30 mg, 20 mg, and combination groups,
respectively, and the difference was not statistically sig-
nificant (p = 0.2738).
The CPK levels at grade 3 or higher were reported in
4, 1, and 3 patients in the clevudine 30 mg, 20 mg, and
combination groups, respectively, during the study. Two
patients out of eight with CPK elevation of more than
grade 3 showed muscle-related symptoms in the clevudine
30 mg group and discontinued clevudine therapy. The
other six patients continued therapy, and their CPK levels
stabilized.
Discussion
The baseline characteristics of the three groups were well
balanced in this randomized study.
Fig. 1 Mean changes from
baseline in HBV DNA. Mean
HBV DNA changes from
baseline at week 96 were -4.32,
-4.86, and -5.26 log10 copies/ml
in the clevudine 30 mg, clevudine
20 mg, and combination groups,
respectively, which did not show
a statistically significant
difference (p\0.3534)
Table 3 Viral dynamic over 24 weeks
Parameter Group Nb N Missc Mean SD Median Min. Max. p valuea
e CLV 30 mg 24 1 0.877 0.201 0.959 0.120 1.000 0.934
CLV 20 mg 23 0 0.927 0.085 0.957 0.653 0.994
CLV ? ADV 20 3 0.911 0.095 0.959 0.703 1.000
l CLV 30 mg 24 1 1.672 2.000 0.761 0.150 6.331 0.489
CLV 20 mg 23 0 2.026 2.199 1.063 0.304 6.419
CLV ? ADV 20 3 1.817 1.927 0.826 0.261 6.083
a CLV 30 mg 24 1 0.139 0.123 0.121 0.003 0.495 0.173
CLV 20 mg 23 0 0.166 0.083 0.130 0.056 0.337
CLV ? ADV 20 3 0.127 0.099 0.078 0.003 0.320
a Kruskal–Wallis test
b Patients (CLV 30 mg: 013-R010, CLV 20 mg ? ADV 10 mg: 013-R006, 062-R004, 062-R008) were excluded because of numerical issues
(estimates were biased)
c Patients (CLV 20 mg: 013-R007, CLV 20 mg ? ADV 10 mg: 022-R001) were excluded because of dropping out before 24 weeks
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Based on the viral dynamics study over 24 weeks of
treatment, it was speculated that the antiviral activity of the
combination of clevudine 20 mg and adefovir 10 mg was
as good as that of clevudine 30 mg.
Clevudine is known to have highly potent antiviral
activity. However, the emergence of resistance during
therapy is a limitation to long-term treatment. The com-
bination of clevudine 20 mg and adefovir also provided
very potent antiviral activity, although the dose of clevu-
dine was reduced from 30 to 20 mg.
The proportion of patients with HBV DNA less than 300
copies/ml by real-time PCR at week 96 was higher in the
combination group (95 %) compared to the clevudine
monotherapy groups (67, 71 %) (p \ 0.0376), which
resulted from the viral breakthrough led by the emergence
of resistance in the clevudine monotherapy groups.
Although direct head-to-head comparisons are not avail-
able, the antiviral activity of the combination was similar to
that of tenofovir (76 % HBeAg-positive and 93 % HBeAg-
negative patients with HBV DNA less than 400 copies/ml
at week 48) [21]. We also evaluated the proportion of
patients with HBV DNA less than 116 copies/ml by real-
time PCR: 86 % in the combination of clevudine 20 mg
and adefovir group. This result demonstrated remarkable
viral suppression activity by the combination therapy. For
the patients with liver cirrhosis at baseline, the proportions
of patients with HBV DNA levels less than 300 copies/ml
did not show statistically significant differences among the
three groups at week 96 (p = 1.000, data not shown).
In this study, it was demonstrated that combination
therapy with clevudine 20 mg and adefovir did not induce
resistance, while 20 % of resistance was reported in the
clevudine monotherapy groups. Clevudine is a nucleoside
analog and shows cross resistance to lamivudine and tel-
bivudine, which belong to the same group of nucleoside
analogs. In contrast, adefovir is a nucleotide analog.
Therefore, we can speculate that combination therapy with
different structures would have an advantage over mono-
therapy on emergence of resistance.
The biochemical response, which was defined as the
proportion of normal ALT at week 96, was similar among
the three groups (p = 0.4053). We had a limitation in the
evaluation of serological response because 28–38 % of
HBeAg-negative patients were included in each group,
including a small number of patients.
Also, we investigated the hepatitis B surface antigen
(HBsAg) reduction in 57 patients who completed the week 96
visit. The mean declines of HBsAg level from baseline were
-0.03 ± 0.53, -0.18 ± 0.32, and -0.25 ± 0.47 log IU/ml
in the clevudine 30 mg, 20 mg, and combination groups,
respectively. In our study, HBsAg reduction was not obvious,
although HBsAg reduction by clevudine has been published in
previous papers [22, 23]. In consideration of the low level of
baseline HBsAg (3.53–3.66 log IU/ml) in this study, we can
presume that HBsAg reduction by clevudine is more pre-
dominant in patients with high baseline HBsAg levels.
Adefovir dipivoxil is known to develop nephrotoxicity
with serum creatinine elevation during administration [24].
Therefore, we investigated the change in serum creatinine
in the combination groups, which did not show a statisti-
cally significant difference at week 96 from baseline (data
not shown). No patients showed symptoms of nephrotoxi-
city during the treatment period.
During the 2-year treatment period, muscle weakness was
reported in three patients treated with clevudine only. Two
patients with muscle weakness in the clevudine 20 mg group
continued with the study, and the symptom disappeared during
clevudine treatment. One patient with muscle weakness in the
clevudine 30 mg group discontinued with the study. The
symptom of this patient was resolved after stopping clevudine
treatment. Two patients with myalgia reported (1 in the clevu-
dine 30 mg and 1 in the combination group) continued with the
study, and their symptoms were resolved during the study.
We planned to investigate whether the dose reduction of
clevudine from 30 to 20 mg would affect the incident rate of
myopathy by clevudine. Considering these data, it is hard to
conclude that the dose of clevudine is connected to muscle-
related symptoms. In our study, there was no relationship
between muscle weakness and CPK elevation, while it seemed
that muscle weakness was followed by CPK elevation.
Due to the limitation of the sample size, a large-scale
clinical study is required for the evaluation of the rela-
tionship between muscle-related symptoms and the dose, as
well as the efficacy of combination therapy.
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